Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Phase 2/3 Clinical Study to Investigate Safety and Immunogenicity of a Single VLA2001 Booster Vaccination in Adult Volunteers, After Receipt of Nationally Rolled Out mRNA COVID-19 Vaccines and/or Natural SARS-CoV-2 Infection

NCT05364242 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT05364242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05364242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Phase 2/3 Clinical Study to Investigate Safety and Immunogenicity of a Single VLA2001 Booster Vaccination in Adult Volunteers, After Receipt of Nationally Rolled Out mRNA COVID-19 Vaccines and/or Natural SARS-CoV-2 Infection
Lead sponsor
Valneva Austria GmbH
Phase
Phase 2/3
Overall status
Completed
Start date
May 9, 2022
Completion date
May 22, 2023
Enrollment
178 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection